Lunai Bioworks, an AI-driven life sciences company focused on central nervous system and oncology drug discovery, announced it has executed a binding $20 million strategic transaction to acquire a blood-brain barrier delivery platform along with central nervous system Alzheimer’s drug assets from the Clemann Group.
The transaction is structured as Series B Convertible Preferred equity with a fixed conversion price of $1.50 per share and includes a 19.9% beneficial ownership cap. The company emphasized that the structure contains no variable pricing or reset provisions, supporting its equity position while maintaining Nasdaq compliance.
The acquired platform is designed to address one of the most significant challenges in CNS drug development, the ability to effectively deliver therapeutics into the brain. According to the company, the technology enables compounds to cross the blood-brain barrier, remain inactive in the body, and then activate specifically within the brain. The mechanism of action targets pathways associated with acetylcholinesterase modulation, which are central to many neurological diseases.
Lunai said the acquisition strengthens its Alzheimer’s pipeline by combining its capabilities in identifying biological targets with a validated delivery mechanism. The company also noted that the platform expands its potential to develop treatments across a broader range of CNS disorders, where traditional therapies often fail to penetrate the brain effectively, potentially improving both safety and efficacy outcomes.
The company added that its broader platform integrates clinical data, machine learning, and in vivo validation to accelerate drug discovery and improve clinical success rates, with a particular focus on complex CNS and oncology diseases.
KEY QUOTE:
“This is a step-change in our capabilities. We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain. This has profound implications for how we treat Alzheimer’s and other complex CNS diseases that have historically been unreachable.”
David Weinstein, CEO Of Lunai Bioworks
